Mechanisms of Resistance to first-line Osimertinib in Hispanic patients with EGFR mutant non-small cell lung cancer (FRESTON-CLICaP).

Cardona AF;Ruiz-Patiño A;Recondo G;Martín C;Raez L;Samtani S;Minata JN;Blaquier JB;Enrico D;Burotto M;Ordóñez-Reyes C;Chamorro DF;Garcia-Robledo JE;Corrales L;Zatarain-Barrón ZL;Más L;Sotelo C;Ricaurte L;Santoyo N;Cuello M;Mejía S;Jaller E;Vargas C;Carranza H;Otero J;Rodríguez J;Archila P;Bermudez M;Gamez T;de Lima VC;Freitas H;Russo A;Polo C;Malapelle U;Perez D de M;Rolfo C;Viola L;Rosell R;Arrieta O

2022-01-01